|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
DISULFIRAM CHRONIC TREATMENT MAY CAUSE REDUCED METABOLISM OF THE DRUG LEADING TO INCREASED PLASMA LEVELS & PROLONGED HALF LIFE OF THE DRUG
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
ERYTHROMYCIN DECREASES CLEARANCE OF BENZODIAZEPINES, THUS INCREASE THE PHARMACOLOGIC EFFECT OF THE DRUG SO THEIR DOSE SHOULD BE REDUCED TO 1/3
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
ERYTHROMYCIN DECREASES CLEARANCE OF BENZODIAZEPINES, THUS INCREASE THE PHARMACOLOGIC EFFECT OF THE DRUG SO THEIR DOSE SHOULD BE REDUCED TO 1/3
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
BENZODIAZEPINES DOSE IS TO BE INCREASED TO ACHIEVE SEDATION ON CONCOMITANT USE. DOSE SHOULD BE REDUCED ONCE THEOPHYLLINE IS WITHDRAWN OTHERWISE TOXICITY APPEARS
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
ERYTHROMYCIN DECREASES CLEARANCE OF BENZODIAZEPINES, THUS INCREASE THE PHARMACOLOGIC EFFECT OF THE DRUG SO THEIR DOSE SHOULD BE REDUCED TO 1/3
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
INCREASED SEDATIVE EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
ORAL CONTRACEPTIVES INCREASE ITS PLASMA CONCENTRATION BY 15-20%
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
MAY INCREASE DROWSINESS EFFECT
|
ERYTHROMYCIN DECREASES CLEARANCE OF BENZODIAZEPINES, THUS INCREASE THE PHARMACOLOGIC EFFECT OF THE DRUG SO THEIR DOSE SHOULD BE REDUCED TO 1/3
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BENZODIAZEPINES CAN CAUSE RESPIRATORY DEPRESSION BUT DOSE OF BARBITURATE IS DECREASED
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
MAY INCREASE DROWSINESS EFFECT
|
PROBENECID INCREASES THE HALF LIFE OF THE DRUG
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF POSTOPERATIVE RESPIRATORY DEPRESSION OR ENHANCE IT
|
MAY INCREASE DROWSINESS EFFECT
|